Literature DB >> 21493697

Effect of pulmonary rehabilitation on peripheral muscle fiber remodeling in patients with COPD in GOLD stages II to IV.

Ioannis Vogiatzis1, Gerasimos Terzis2, Grigoris Stratakos3, Evgenia Cherouveim4, Dimitris Athanasopoulos5, Stauroula Spetsioti5, Ioannis Nasis5, Panagiota Manta6, Charis Roussos3, Spyros Zakynthinos3.   

Abstract

BACKGROUND: In most patients with COPD, rehabilitative exercise training partially reverses the morphologic and structural abnormalities of peripheral muscle fibers. However, whether the degree of improvement in muscle fiber morphology and typology with exercise training varies depending on disease severity remains unknown.
METHODS: Forty-six clinically stable patients with COPD classified by GOLD (Global Initiative for Obstructive Lung Disease) as stage II (n = 14), III (n = 18), and IV (n = 14) completed a 10-week comprehensive pulmonary rehabilitation program consisting of high-intensity exercise three times weekly.
RESULTS: At baseline, muscle fiber mean cross-sectional area and capillary density did not significantly differ between patients with COPD and healthy control subjects, whereas muscle fiber type I and II proportion was respectively lower (P < .001) and higher (P < .002) in patients with GOLD stage IV compared with healthy subjects and patients with GOLD stages II and III. Exercise training improved, to a comparable degree, functional capacity and the St. George Respiratory Questionnaire health-related quality of life score across all three GOLD stages. Vastus lateralis muscle fiber mean cross-sectional area was increased (P < .001) in all patient groups (stage II: from 4,507 ± 280 μm² to 5,091 ± 271 μm² [14% ± 3%]; stage III: from 3,753 ± 258 μm² to 4,212 ± 268 μm² [14% ± 3%]; stage IV: from 3,961 ± 266 μm² to 4,551 ± 262 μm² [17% ± 5%]), whereas all groups exhibited a comparable reduction (P < .001) in type IIb fiber proportion (stage II: by 6% ± 2%; stage III: by 6% ± 1%; stage IV: by 7% ± 1%) and an increase (P < .001) in capillary to fiber ratio (stage II: from 1.48 ± 0.10 to 1.81 ± 0.10 [23% ± 5%]; stage III: from 1.29 ± 0.06 to 1.56 ± 0.09 [21% ± 5%]; stage IV: from 1.43 ± 0.10 to 1.71 ± 0.13 [18 ± 3%]). The magnitude of changes in the aforementioned variables did not differ across GOLD stages.
CONCLUSIONS: Functional capacity and morphologic and typologic adaptations to rehabilitation in peripheral muscle fibers were similar across GOLD stages II to IV. Pulmonary rehabilitation should be implemented in patients at all COPD stages.

Entities:  

Mesh:

Year:  2011        PMID: 21493697     DOI: 10.1378/chest.10-3058

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  33 in total

1.  Are the Effects of High-Intensity Exercise Training Different in Patients with COPD Versus COPD+Asthma Overlap?

Authors:  Antenor Rodrigues; Joice Mara de Oliveira; Karina Couto Furlanetto; Felipe Vilaça Cavallari Machado; Letícia Fernandes Belo; Lorena Paltanin Schneider; Andrea Akemi Morita; Ana Carolina Andrelo; Jéssica Fonseca; Igor Lopes Brito; Thaís Paes; Josiane Marques Felcar; Vanessa Suziane Probst; Nidia Aparecida Hernandes; Fabio Pitta
Journal:  Lung       Date:  2019-12-23       Impact factor: 2.584

Review 2.  Clinical management of chronic obstructive pulmonary disease patients with muscle dysfunction.

Authors:  Joaquim Gea; Carme Casadevall; Sergi Pascual; Mauricio Orozco-Levi; Esther Barreiro
Journal:  J Thorac Dis       Date:  2016-11       Impact factor: 2.895

Review 3.  Defining COPD-Related Comorbidities, 2004-2014.

Authors:  Carlos H Martinez; David M Mannino; Miguel J Divo
Journal:  Chronic Obstr Pulm Dis       Date:  2014-05-06

Review 4.  ERS International Congress 2017: a peek of outstanding abstracts from the clinical assembly.

Authors:  Nicolas Kahn; Vasileios Andrianopoulos; Evgeni Mekov; Felix J F Herth
Journal:  J Thorac Dis       Date:  2017-11       Impact factor: 2.895

Review 5.  Can muscle protein metabolism be specifically targeted by exercise training in COPD?

Authors:  Davina C M Simoes; Ioannis Vogiatzis
Journal:  J Thorac Dis       Date:  2018-05       Impact factor: 2.895

Review 6.  Muscle dysfunction in chronic obstructive pulmonary disease: update on causes and biological findings.

Authors:  Joaquim Gea; Sergi Pascual; Carme Casadevall; Mauricio Orozco-Levi; Esther Barreiro
Journal:  J Thorac Dis       Date:  2015-10       Impact factor: 2.895

Review 7.  An official American Thoracic Society/European Respiratory Society statement: update on limb muscle dysfunction in chronic obstructive pulmonary disease.

Authors:  François Maltais; Marc Decramer; Richard Casaburi; Esther Barreiro; Yan Burelle; Richard Debigaré; P N Richard Dekhuijzen; Frits Franssen; Ghislaine Gayan-Ramirez; Joaquim Gea; Harry R Gosker; Rik Gosselink; Maurice Hayot; Sabah N A Hussain; Wim Janssens; Micheal I Polkey; Josep Roca; Didier Saey; Annemie M W J Schols; Martijn A Spruit; Michael Steiner; Tanja Taivassalo; Thierry Troosters; Ioannis Vogiatzis; Peter D Wagner
Journal:  Am J Respir Crit Care Med       Date:  2014-05-01       Impact factor: 21.405

Review 8.  Pathobiological mechanisms underlying metabolic syndrome (MetS) in chronic obstructive pulmonary disease (COPD): clinical significance and therapeutic strategies.

Authors:  Stanley M H Chan; Stavros Selemidis; Steven Bozinovski; Ross Vlahos
Journal:  Pharmacol Ther       Date:  2019-02-26       Impact factor: 12.310

Review 9.  Comprehensive care for chronic obstructive pulmonary disease.

Authors:  Fanny Wai San Ko; Ka Pang Chan; David Shu Cheong Hui
Journal:  J Thorac Dis       Date:  2019-10       Impact factor: 2.895

10.  Skeletal Muscle Dysfunction in Chronic Obstructive Pulmonary Disease. What We Know and Can Do for Our Patients.

Authors:  Ariel Jaitovich; Esther Barreiro
Journal:  Am J Respir Crit Care Med       Date:  2018-07-15       Impact factor: 21.405

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.